• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W.L. GORE & ASSOCIATES AORTIC EXCLUDER AAA ENDOPROSTHESIS (C3); SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W.L. GORE & ASSOCIATES AORTIC EXCLUDER AAA ENDOPROSTHESIS (C3); SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Catalog Number RLT281218
Device Problems Adverse Event Without Identified Device or Use Problem (2993); No Apparent Adverse Event (3189)
Patient Problems Aneurysm (1708); No Code Available (3191)
Event Date 01/15/2016
Event Type  Injury  
Manufacturer Narrative
(b)(4).According to the gore® excluder® endoprosthesis instructions for use (ifu), adverse events that may occur and/or require intervention include, but are not limited to aneurysm enlargement and endoleak.Users are made aware of the risks associated with type ii endoleaks in the ifu and are instructed to consider the risks and benefits discussed in the ifu for each patient before using the devices.The date of event will be used as (b)(6) 2016 - the date of aneurysm enlargement.
 
Event Description
On (b)(6) 2015, this patient underwent endovascular treatment for an abdominal aortic aneurysm measuring 60 mm in diameter, and was implanted with gore® excluder® endoprostheses.The patient tolerated the procedure.It was reported that on (b)(6) 2017, a type ii endoleak was identified and the patient underwent an embolization procedure.No further adverse events have been reported.On (b)(6) 2016, follow-up cta showed that a maximum diameter of the aortic aneurysm/lesion was 64 mm.
 
Manufacturer Narrative
(b)(4).
 
Event Description
It was reported that on (b)(6) 2017, a type ii endoleak was identified and the patient underwent a coil embolization procedure of the iliolumbar artery.On (b)(6) 2018, a type ii endoleak was identified and the patient underwent a coil embolization procedure.The patient tolerated the procedure.No further adverse events have been reported.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AORTIC EXCLUDER AAA ENDOPROSTHESIS (C3)
Type of Device
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
W.L. GORE & ASSOCIATES
flagstaff AZ
Manufacturer (Section G)
MEDICAL PHOENIX 2 B/P
32470 n. north valley parkway
phoenix AZ 85085
Manufacturer Contact
nataliya baramzina
1500 n. 4th street
flagstaff, AZ 
9285263030
MDR Report Key7151688
MDR Text Key95949952
Report Number3007284313-2017-00320
Device Sequence Number1
Product Code MIH
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P020004
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type study
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 04/05/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/28/2017
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date09/15/2018
Device Catalogue NumberRLT281218
Device Lot Number14274912
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured09/16/2015
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age80 YR
Patient Weight63
-
-